サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1541258

降圧剤市場レポート：薬剤クラス別、タイプ別、流通チャネル別、地域別、2024～2032年

Antihypertensive Drugs Market Report by Therapeutic Class, Type, Distribution Channel, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 143 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
降圧剤市場レポート：薬剤クラス別、タイプ別、流通チャネル別、地域別、2024～2032年
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 143 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の降圧剤市場規模は2023年に297億米ドルに達しました。今後、IMARC Groupは、2024～2032年にかけての成長率（CAGR）は2.7％を示し、2032年には380億米ドルに達すると予測しています。高血圧の有病率の増加、CVDに罹患する患者数の増加、臨床研究数の増加が市場を牽引する主要因のひとつです。

降圧剤は、動脈壁に対する血液の力が高くなり、心臓病、脳卒中、その他の健康問題のリスクを高める可能性のある高血圧症の治療に利用されます。一般に、利尿薬、β遮断薬、カルシウム拮抗薬、アンジオテンシン変換酵素（ACE）阻害薬、血管拡大薬で構成されます。血管拡大薬は、血管を弛緩させ、血管内の水分量を減らし、血管を収縮させるホルモンの量を減らすことによって作用します。また、心拍を遅くし、収縮期血圧を健康に保ち、寿命を延ばし、早死のリスクを最小限に抑えます。現在、主要企業は製品ポートフォリオを拡大するため、イミダゾリン系、モナテピル系、中性エンドペプチダーゼ阻害剤を導入しています。

降圧剤市場動向

個人における高血圧と高BPの急増は、世界中で降圧薬の需要を牽引する主要要因の一つです。さらに、これらの疾患を発症しやすい高齢者人口の増加が市場にプラスの影響を与えています。さらに、座りがちなライフスタイル、不健康な食事パターン、高ストレスレベル、糖尿病、肥満が原因で心血管疾患（CVD）を患う患者が増加していることも、市場の成長を後押ししています。これとは別に、多くの国の行政機関が、高血圧症、その症状、診断、治療に関する認識を広めるためのキャンペーンを開始しています。このことと、高血圧の新しい治療法を開発するための臨床研究や臨床試験の数が増加していることが相まって、市場の成長を強化しています。さらに、医療費用の拡大を背景に、BP関連疾患の治療に市販薬（OTC）の使用が増加していることも、市場に明るい展望をもたらしています。これに加えて、消費者が必要とする用量に応じて降圧剤を提供するオンライン小売プラットフォームが増加しています。これは、製薬業界とeコマース業界の著しい成長とともに、市場の成長を促進しています。さらに、高血圧治療に経済的支援を提供し、医療費用を最小限に抑える健康保険の導入が増加していることも、市場の成長を後押ししています。

本レポートで扱う主要質問

  • 世界の降圧剤市場はこれまでどのように推移してきたか？
  • 世界の降圧剤市場における促進要因、抑制要因、機会は何か？
  • 各駆動要因、抑制要因、機会が世界の降圧剤市場に与える影響は？
  • 主要な地域市場とは？
  • 最も魅力的な降圧剤市場はどの国か？
  • 薬剤クラス別の市場内訳は？
  • 降圧剤市場で最も魅力的な治療クラスはどれか？
  • タイプ別の市場内訳は？
  • 降圧剤市場で最も魅力的なタイプは？
  • 流通チャネル別の市場内訳は？
  • 降圧剤市場で最も魅力的な流通チャネルは？
  • 世界の降圧剤市場の競合構造は？
  • 世界の降圧剤市場における主要参入企業/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の降圧剤市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：セラピークラス別

  • 利尿剤
  • ACE阻害薬
  • カルシウムチャネル遮断薬
  • ベータ遮断薬
  • 血管拡大薬
  • その他

第7章 市場内訳：タイプ別

  • 原発性高血圧
  • 二次性高血圧

第8章 市場内訳：流通チャネル別

  • 小売薬局
  • 病院薬局
  • eコマース

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • AstraZeneca
    • Boehringer Ingelheim International GmbH
    • Daiichi Sankyo Company Limited
    • Johnson & Johnson Services Inc.
    • Lupin Pharmaceuticals Inc
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • Sun Pharmaceutical Industries Ltd.
図表

List of Figures

  • Figure 1: Global: Antihypertensive Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Antihypertensive Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Antihypertensive Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Antihypertensive Drugs Market: Breakup by Therapeutic Class (in %), 2023
  • Figure 5: Global: Antihypertensive Drugs Market: Breakup by Type (in %), 2023
  • Figure 6: Global: Antihypertensive Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Antihypertensive Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Antihypertensive Drugs (Diuretics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Antihypertensive Drugs (Diuretics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Antihypertensive Drugs (ACE Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Antihypertensive Drugs (ACE Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Antihypertensive Drugs (Calcium Channel Blockers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Antihypertensive Drugs (Calcium Channel Blockers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Antihypertensive Drugs (Beta-adrenergic Blockers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Antihypertensive Drugs (Beta-adrenergic Blockers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Antihypertensive Drugs (Vasodilators) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Antihypertensive Drugs (Vasodilators) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Antihypertensive Drugs (Other Therapeutic Classes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Antihypertensive Drugs (Other Therapeutic Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Antihypertensive Drugs (Primary Hypertension) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Antihypertensive Drugs (Primary Hypertension) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Antihypertensive Drugs (Secondary Hypertension) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Antihypertensive Drugs (Secondary Hypertension) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Antihypertensive Drugs (Retail Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Antihypertensive Drugs (Retail Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Antihypertensive Drugs (Hospital Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Antihypertensive Drugs (Hospital Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Antihypertensive Drugs (E-Commerce) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Antihypertensive Drugs (E-Commerce) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: North America: Antihypertensive Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: North America: Antihypertensive Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: United States: Antihypertensive Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: United States: Antihypertensive Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Canada: Antihypertensive Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Canada: Antihypertensive Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Asia-Pacific: Antihypertensive Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Asia-Pacific: Antihypertensive Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: China: Antihypertensive Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: China: Antihypertensive Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Japan: Antihypertensive Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Japan: Antihypertensive Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: India: Antihypertensive Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: India: Antihypertensive Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: South Korea: Antihypertensive Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: South Korea: Antihypertensive Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Australia: Antihypertensive Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Australia: Antihypertensive Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Indonesia: Antihypertensive Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Indonesia: Antihypertensive Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Others: Antihypertensive Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Others: Antihypertensive Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Europe: Antihypertensive Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Europe: Antihypertensive Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Germany: Antihypertensive Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Germany: Antihypertensive Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: France: Antihypertensive Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: France: Antihypertensive Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: United Kingdom: Antihypertensive Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: United Kingdom: Antihypertensive Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Italy: Antihypertensive Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Italy: Antihypertensive Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Spain: Antihypertensive Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Spain: Antihypertensive Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Russia: Antihypertensive Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Russia: Antihypertensive Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Others: Antihypertensive Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Others: Antihypertensive Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Latin America: Antihypertensive Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Latin America: Antihypertensive Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Brazil: Antihypertensive Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Brazil: Antihypertensive Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Mexico: Antihypertensive Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Mexico: Antihypertensive Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Others: Antihypertensive Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Others: Antihypertensive Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Middle East and Africa: Antihypertensive Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Middle East and Africa: Antihypertensive Drugs Market: Breakup by Country (in %), 2023
  • Figure 78: Middle East and Africa: Antihypertensive Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Global: Antihypertensive Drugs Industry: SWOT Analysis
  • Figure 80: Global: Antihypertensive Drugs Industry: Value Chain Analysis
  • Figure 81: Global: Antihypertensive Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Antihypertensive Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Antihypertensive Drugs Market Forecast: Breakup by Therapeutic Class (in Million US$), 2024-2032
  • Table 3: Global: Antihypertensive Drugs Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 4: Global: Antihypertensive Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Antihypertensive Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Antihypertensive Drugs Market: Competitive Structure
  • Table 7: Global: Antihypertensive Drugs Market: Key Players
目次
Product Code: SR112024A4190

The global antihypertensive drugs market size reached US$ 29.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 38.0 Billion by 2032, exhibiting a growth rate (CAGR) of 2.7% during 2024-2032. The increasing prevalence of hypertension, rising number of patients suffering from CVDs, and the growing number of clinical studies represent some of the key factors driving the market.

Antihypertensive drugs are utilized to treat hypertension wherein the force of blood against the walls of the arteries becomes high and can increase the risk of heart disease, stroke, and other health problems. They generally comprise diuretics, beta-blockers, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, and vasodilators. They work by relaxing the blood vessels, reducing the amount of fluid in the blood vessels, and decreasing the amount of hormones that cause blood vessels to constrict. They also slow down the heartbeat, maintain a healthy systolic BP, improve life expectancy, and minimize the risk of premature death. At present, key players are introducing imidazolines, monatepil, and neutral endopeptidase inhibitors to expand their product portfolio.

Antihypertensive Drugs Market Trends:

The surging prevalence of hypertension and high BP among individuals represents one of the major factors driving the demand for antihypertensive drugs around the world. Moreover, the growing geriatric population that is susceptible to developing these medical disorders is influencing the market positively. In addition, the increasing number of patients suffering from cardiovascular diseases (CVDs) on account of sedentary lifestyles, unhealthy dietary patterns, high-stress levels, diabetes, and obesity among the masses is favoring the growth of the market. Apart from this, governing agencies of numerous countries are initiating campaigns to spread awareness about the hypertension disorder, its symptoms, diagnosis, and treatment. This, coupled with the rising number of clinical studies and trials to develop new treatments for hypertension, is strengthening the growth of the market. Furthermore, the growing usage of over the counter (OTC) drugs to treat BP-related diseases on account of expanding healthcare costs is creating a positive outlook for the market. Besides this, there is a rise in the number of online retail platforms that offer antihypertensive drugs according to the dosage needed by the consumer. This, along with significant growth in the pharmaceutical and e-commerce industries, is propelling the growth of the market. Additionally, the increasing adoption of health insurance policies that provide financial assistance for hypertension treatment and minimize healthcare expenses is impelling the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global antihypertensive drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on therapeutic class, type and distribution channel.

Therapeutic Class Insights:

Diuretics

ACE Inhibitors

Calcium Channel Blockers

Beta-adrenergic Blockers

Vasodilators

Others

The report has provided a detailed breakup and analysis of the antihypertensive drugs market based on the therapeutic class. This includes diuretics, ACE inhibitors, calcium channel blockers, beta-adrenergic blockers, vasodilators, and others. According to the report, calcium channel blockers represented the largest segment.

Type Insights:

Primary Hypertension

Secondary Hypertension

A detailed breakup and analysis of the antihypertensive drugs market based on the type has also been provided in the report. This includes primary hypertension and secondary hypertension. According to the report, primary hypertension accounted for the largest market share.

Distribution Channel Insights:

Retail Pharmacy

Hospital Pharmacy

E-Commerce

The report has provided a detailed breakup and analysis of the antihypertensive drugs market based on the distribution channel. This includes retail pharmacy, hospital pharmacy, and e-commerce. According to the report, hospital pharmacy represented the largest segment.

Regional Insights:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for antihypertensive drugs. Some of the factors driving the North America antihypertensive drugs market included expansion of online pharmacies, government initiatives, product innovation, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global antihypertensive drugs market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include AstraZeneca, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Johnson & Johnson Services Inc., Lupin Pharmaceuticals Inc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global antihypertensive drugs market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global antihypertensive drugs market?
  • What is the impact of each driver, restraint, and opportunity on the global antihypertensive drugs market?
  • What are the key regional markets?
  • Which countries represent the most attractive antihypertensive drugs market?
  • What is the breakup of the market based on the therapeutic class?
  • Which is the most attractive therapeutic class in the antihypertensive drugs market?
  • What is the breakup of the market based on the type?
  • Which is the most attractive type in the antihypertensive drugs market?
  • What is the breakup of the market based on the distribution channel?
  • Which is the most attractive distribution channel in the antihypertensive drugs market?
  • What is the competitive structure of the global antihypertensive drugs market?
  • Who are the key players/companies in the global antihypertensive drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Antihypertensive Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapeutic Class

  • 6.1 Diuretics
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 ACE Inhibitors
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Calcium Channel Blockers
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Beta-adrenergic Blockers
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Vasodilators
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Type

  • 7.1 Primary Hypertension
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Secondary Hypertension
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Retail Pharmacy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Hospital Pharmacy
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 E-Commerce
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AstraZeneca
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Boehringer Ingelheim International GmbH
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Daiichi Sankyo Company Limited
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Johnson & Johnson Services Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Lupin Pharmaceuticals Inc
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Merck & Co. Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Novartis AG
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Sanofi
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Sun Pharmaceutical Industries Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis